INVESTOR RESOURCES

iCHOR COMPANY INFORMATION, NEWS & PRESENTATIONS

Corporate Overview

iCHOR was founded by Interventional Radiologist Dr. Troy Long and industry veteran Tim Blair who saw an opportunity to develop new technologies to address the large unmet needs in treating peripheral vascular occlusions.  They have devised a technology that has converted the tried and proven Fogarty balloon sweep method from an open surgery to a minimally-invasive endovascular procedure.

The overall corporate objective is to focus on creating a one-size-fits-all system that replicates successful parameters of surgical clot removal while addressing the shortcomings of current therapeutic options. The Team’s long-term vision is for the iSWEEP system to become the standard of care and first-line therapy for treating peripheral vascular occlusions, increasing clinical flexibility while delivering improved outcomes at a lower cost.

The iCHOR team consists of a group of experienced multi-disciplinary members, including entrepreneurs, executives, physicians, regulatory experts, and engineers. Together, we bring a broad range of experience in the development, regulatory approval, and commercialization of medical devices in the peripheral vascular space.

Quick Resources

PITCH DECKS

NAMSA CASE STUDY

iCHOR at LSI '24

Medline Review Articles

The Latest News

Simplified Mechanical Thrombectomy Opens New Opportunities for ASCs and OBLs

Ambulatory Surgery Centers (ASCs) and Office-Based Labs (OBLs) are emerging as compelling alternatives to hospital-based care, offering patients better access at substantially lower cost. As site-of-care reimbursement evolves and technology matures, peripheral thrombectomy is now becoming economically viable in these settings. iCHOR Vascular’s iSWEEP platform is accelerating this shift through intentional simplicity: no capital equipment, minimal setup, predictable costs, and…

Understanding the Total Cost of Procedures for Thrombectomies

Hospitals routinely underestimate the true cost of thrombectomy because they focus on device price instead of the full episode of care. This article argues for a broader, “total cost” view that captures all direct and indirect drivers of financial performance around clot-removal procedures. Why “total cost” matters Most thrombectomy cost discussions center on device list price, yet materials are only…

Investor Relations

Contact Us

    P.O. Box 810787 Boca Raton, FL 33481

    + 1 954-483-4525

    info@ichorvascular.com